A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML

Clinical trial NCT02326584 · COMPLETED

Trial details

NCT number: NCT02326584
Sponsor: Seagen Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Acute Myelogenous Leukemia

Start date: 2014-12-01
Primary completion: 2017-01-30
Enrollment: 116

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.